Escherichia coli

1. Overview

Escherichia coli is a Gram-negative rod-shaped bacterium belonging to the family Enterobacteriaceae and the genus Escherichia. It is the predominant aerobic commensal in the human and warm-blooded animal intestinal tract and is one of the most intensively studied model microorganisms worldwide. E. coli is a facultative anaerobe exhibiting extensive phenotypic and genotypic diversity. Its genome undergoes constant change, with genome sizes varying by up to 1.9 Mb and encoding approximately 4,000–6,500 proteins; the core genome comprises only about 2,000 genes.

E. coli strains can be broadly divided into three families: (1) commensal organisms, normal residents of the gastrointestinal tract that do not cause disease; (2) intestinal pathogenic E. coli (InPEC) , including enteropathogenic E. coli (EPEC), enterotoxigenic E. coli (ETEC), enterohemorrhagic E. coli (EHEC), enteroaggregative E. coli (EAEC), enteroinvasive E. coli (EIEC), and diffusely adherent E. coli (DAEC); and (3) extraintestinal pathogenic E. coli (ExPEC) , which usually cause disease outside the intestinal tract, including uropathogenic E. coli (UPEC) and neonatal meningitis E. coli (NMEC). E. coli causes an estimated 950,000 deaths annually and is one of the leading bacterial pathogens worldwide.

2. Background Information

2.1 What is Escherichia coli?

E. coli is a Gram-negative facultative anaerobic bacillus of the family Enterobacteriaceae, first described by Theodor Escherich in 1919. It is a major member of the normal human gut microbiota, but certain strains can acquire pathogenicity and cause a spectrum of diseases ranging from mild diarrhea to fatal systemic infections.

The E. coli genome is highly plastic, consisting of a core genome and an accessory genome. The core genome contains approximately 2,000 genes, mostly non-mobile elements; strain-specific genes are more likely located on pathogenicity islands, which are large genomic regions containing virulence-related genes found in pathogenic strains but not commensal strains, as well as mobile elements including plasmids, bacteriophages, insertion sequence elements, transposons, and integrons. Only about 20% of coding sequences are shared among all strains, with ~64% of sequences shared between commensal and ExPEC strains. E. coli can be divided into 9 phylogenetic groups (A, B1, B2, C, D, E, F, G, etc.).

2.2 E. coli Genome & Classification

The E. coli genome ranges from approximately 4.6–5.9 Mb, encoding approximately 4,000–6,500 proteins, with a core genome of only about 2,000 genes. The pan-genome of the accessory genome is estimated to contain over 17,000 different genes. E. coli classification is based on pathotype, primarily determined by the presence or absence of specific virulence factors and pathogenicity islands.

2.3 What Are E. coli Proteins?

E. coli virulence factors can be categorized as follows:

2.3.1 Adhesins

2.3.2 Secretion Systems

The Type III Secretion System (T3SS) is the core virulence mechanism of EPEC and EHEC, encoded by the LEE pathogenicity island. The T3SS comprises approximately 20 proteins, including structural components escV (inner membrane pore), escD (base structure), and secreted effector proteins EspA, EspB, EspD. This system injects effector proteins directly into host cells, causing attaching and effacing (A/E) lesions that damage intestinal epithelial cells.

2.3.3 Toxins

2.4 Mechanism of Infection and Pathogenesis

The infection mechanisms of E. coli are not a single process but a highly diverse set of strategies determined by the pathotype. Different pathotypes acquire specific virulence factors and employ distinct "tactics" to colonize, invade, damage the host, and evade immunity.

2.4.1 Adhesion and Colonization

The first step of infection is firm attachment to host cell surfaces, acting like an "anchor."

2.4.2 Secretion Systems and Effector Injection

The Type III Secretion System (T3SS) is the core virulence apparatus of EPEC and EHEC, encoded by the locus of enterocyte effacement (LEE) pathogenicity island. Comprising approximately 20 proteins, the T3SS acts as a "molecular syringe," injecting multiple effector proteins (Tir, Map, EspF, etc.) directly into the host cell cytoplasm to hijack cellular functions.

2.4.3 Toxin-Mediated Damage

2.4.4 Infection Strategies of Different Pathotypes

Intestinal Pathotypes: The "Attaching and Effacing" Tactic of EPEC and EHEC

EPEC and EHEC employ the classic "attaching and effacing" (A/E) tactic:

a.      Injection and hijacking: Effector proteins are injected via T3SS. The key effector Tir is inserted into the host cell membrane, serving as the receptor for the bacterial surface adhesin intimin.

b.      Structural disruption: Tir-intimin binding triggers dramatic actin rearrangement, forming an actin pedestal beneath the bacterium and causing effacement of intestinal microvilli, severely impairing intestinal absorption.

c.       Functional disruption: Other effectors (Map, EspF, etc.) disrupt mitochondrial membrane potential and tight junctions, and induce apoptosis.

d.      Toxin attack (EHEC-specific) : After colonization, EHEC releases Shiga-like toxin (Stx) into the bloodstream, attacking endothelial cells in the kidneys and central nervous system, causing HUS.

Extraintestinal Pathotype: The "Invade and Persist" Tactic of UPEC

Uropathogenic E. coli (UPEC) employs a "behind-enemy-lines" tactic, establishing an intracellular "safe haven":

a.      Invasion and intracellular bacterial community formation: UPEC is internalized by bladder epithelial cells via type 1 fimbriae. Some bacteria escape the vesicle and rapidly proliferate in the cytoplasm, forming intracellular bacterial communities (IBCs) .

b.      Establishment of latent reservoirs and immune evasion: After acute infection, UPEC can enter a quiescent state, forming quiescent intracellular reservoirs (QIRs) that persist long-term, evading host immune cells and antibiotics—the root cause of recurrent urinary tract infections.

c.       Hijacking immune signals: UPEC can also bind the CD14 receptor on host immune cells via type 1 fimbriae, hijacking the host immune response and converting it into signals favorable for its own persistence.

2.4.5 Immune Evasion Mechanisms

E. coli has evolved multiple mechanisms to counter the host immune system:

l  Entering a "stealth" state: Inside macrophages, EHEC O157:H7 enters a viable but non-culturable (VBNC) state via the stringent response, significantly reducing pathogen-associated molecular pattern expression, evading macrophage recognition, and becoming more resistant to oxidative stress.

l  Actively suppressing inflammatory signals: Enterotoxigenic E. coli (ETEC) secretes a heat-stable protein factor that blocks activation of the host NF-κB signaling pathway, suppressing inflammation.

l  Interfering with immune cell function: Some E. coli strains (e.g., K1) express outer membrane protein A (OmpA) , which prevents myeloid dendritic cell maturation and induces secretion of immunosuppressive cytokines (IL-10, TGF-β), dismantling adaptive immune responses.

2.4.6 Summary

The infection mechanisms of E. coli represent a sophisticated "toolbox." Different pathotypes selectively employ adhesion, injection, invasion, toxin production, and immune evasion strategies to achieve a spectrum of diseases ranging from intestinal colonization to systemic infection. EPEC/EHEC disrupt the intestinal barrier via "attaching and effacing," while UPEC excels at "sneaking" into cells to establish long-term latent reservoirs. All successful pathotypes must master the art of evading or suppressing the host immune system.

2.5 Symptoms and Treatment

2.5.1 Clinical Symptoms

Clinical manifestations of E. coli infection vary by pathotype and site of infection:

Intestinal infections (ETEC, EPEC, EHEC, etc.):

l  ETEC: Watery diarrhea, the most common cause of traveler's diarrhea

l  EHEC (O157:H7): Sudden severe abdominal cramps with watery diarrhea that may become bloody within 24 hours; diarrhea lasts 1–8 days; approximately 5%–10% of patients develop hemolytic uremic syndrome (HUS)

l  Other symptoms include nausea, vomiting, fever, malaise, and abdominal pain

Extraintestinal infections (ExPEC):

l  Urinary tract infection: Urinary frequency, urgency, dysuria; can progress to pyelonephritis and sepsis

l  Neonatal meningitis: Fever, lethargy, feeding difficulties, seizures

l  Bacteremia: Fever, chills, systemic inflammatory response

l  Peritonitis: Abdominal pain, distension, fever

2.5.2 Treatment

Currently, no specific antiviral therapy is approved for E. coli. Treatment is primarily supportive care and antimicrobial therapy:

Intestinal infections:

l  Fluid replacement: Maintaining water and electrolyte balance is the cornerstone of treatment

l  Antimicrobials: For ETEC traveler's diarrhea, fluoroquinolones, azithromycin, etc., may be used; however, antimicrobials are not recommended for EHEC infection as they can induce Shiga toxin release and increase HUS risk

l  Antidiarrheal agents: Should be used with caution

Extraintestinal infections:

l  Antimicrobials: Selected based on susceptibility results; commonly used agents include fluoroquinolones, third-generation cephalosporins, carbapenems, and aminoglycosides

l  ESBL- or carbapenemase-producing strains require carbapenems or polymyxins

Antimicrobial resistance: Resistance to multiple antimicrobials is increasingly severe. Resistance mechanisms include: target site mutations (e.g., gyrA and parC mutations causing fluoroquinolone resistance), efflux pump overexpression (AcrAB-TolC system), reduced membrane permeability (altered OmpC/OmpF expression), and plasmid-mediated resistance genes (e.g., tet(X4) conferring tigecycline resistance).

2.6 Targets for Intervention

2.6.1 Pathogen Targets

2.6.2 Host Receptors & Entry Factors

2.6.3 Host Signaling Pathways

2.6.4 Immune & Inflammatory Targets

2.7 Vaccine Types and Development Progress

Currently, no licensed E. coli vaccine for human use is available. A 25-year systematic review analyzed 42 clinical trials covering ETEC (34 studies), ExPEC (6 studies), and other pathotypes (2 studies).

2.7.1 Vaccine Platform Types

2.7.2 ETEC Vaccines

ETVAX: An oral vaccine containing four inactivated ETEC strains and LCTBA toxoid; tested in a double-blind trial in Gambian children.

ACE527: Developed by ACE BioSciences and PATH, composed of three live non-toxic strains together producing six ETEC adhesins; completed Phase 1 and Phase 2b trials.

ShigETEC: A live attenuated combined vaccine against shigellosis and ETEC diarrhea; in Phase 1b trials.

2.7.3 ExPEC Vaccines

ExPEC4V, ExPEC10V, ExPEC9V (J&J): Multivalent O-antigen conjugate vaccines; ExPEC9V has entered Phase 3 clinical trials.

Uromune and Uro-Vaxom: Oral vaccines for prevention of recurrent urinary tract infections.

2.7.4 mRNA Vaccines

mRNA-LNP FimH vaccine: A 2025 study published in npj Vaccines developed an mRNA nanoparticle vaccine based on FimH, inducing robust immune responses in mice and representing a promising candidate for UPEC vaccines.

PstS-YidR fusion protein mRNA vaccine: A 2025 study published in npj Vaccines developed next-generation mRNA vaccines encoding a PstS-YidR fusion protein, providing strong protection against EHEC in mice and demonstrating cross-protection against four Enterobacteriaceae species.

2.7.5 Multi-epitope mRNA Vaccines

In 2025, researchers designed multi-epitope mRNA vaccine candidates targeting Shiga toxin 1 (Stx1) using reverse vaccinology.

2.7.6 OMV Vaccines

Intimin-enriched outer membrane vesicles (OMVs) vaccine for controlling intestinal carriage of EHEC.

2.8 Drugs

2.8.1 Pathogen-Targeted Drugs

2.8.2 Host-Targeted Drugs

2.8.2 Phage Therapy

2.8.3 CRISPR Detection Technologies

2.9 Recent Research

2.9.1 Molecular Epidemiology and Resistance Surveillance

A 2026 study published in Microbiology Spectrum reported the novel ST3871 E. coli carrying the tet(X4) resistance gene, exhibiting diverse transmission modes. A 2025 study published in Antibiotics performed genomic and functional characterization of multidrug-resistant E. coli, revealing multiple resistance genes, virulence factors, and efflux pump components, and for the first time implicating the CpxAR two-component system in resistance.I

2.9.2 Host-Pathogen Interactions

A 2026 study published in mSystems found that host norepinephrine rewires the tRNA epitranscriptome of EHEC O157:H7, altering wobble-position modifications and thereby affecting virulence translation. A 2026 study published in mSphere found that sorbose metabolism promotes E. coli fitness and virulence. A 2025 study published in PNAS found that the host innate immune protein β2-microglobulin selectively blocks curli amyloid assembly, effectively inhibiting E. coli biofilm formation.

2.9.3 Quorum Sensing and Tolerance

A 2025 study published in ScienceDirect identified three natural LuxS quorum sensing inhibitors (RHE, MYR, DMY), with RHE and DMY showing synergistic antibacterial effects with colistin and chloramphenicol against multidrug-resistant E. coli. A 2025 study published in PLoS identified single-gene knockout strains hypersusceptible to trimethoprim and chloramphenicol through genome-wide screening, revealing new targets in intrinsic resistance pathways.

2.9.4 Diagnostic Technology Advances

In 2025–2026, significant breakthroughs in E. coli diagnostics included CRISPR-Cas12b/cas12a systems, LAMP-CRISPR/Cas12b combined detection, electrochemical biosensors (detection limit 13.1 CFU/mL), and RPA-CRISPR/Cas12a single-tube integrated detection systems.

2.9.5 Probiotics and Biotherapeutics

A 2025 study published in PubMed developed non-genotoxic EcN 2.0 (a Nissle 1917 variant) overexpressing microcins, which effectively reduces intestinal carriage of ST131 ESBL-E. coli. A 2025 study published in Microbiology Spectrum found that two strains of Bacillus velezensis provide strong probiotic protection against E. coli K99-induced diarrhea.

3. Related Products & Services

l   Recombinant Antigens & Receptors

l   Antibodies

l   Detection Kits

l   Recombinant Protein Expression Services

l   Antibody Development Services

4. Resources

5. References

1.      Blattner, F. R., Plunkett, G., 3rd, Bloch, C. A.,et al. (1997). The complete genome sequence of Escherichia coli K-12. Science (New York, N.Y.), 277(5331), 1453–1462.

2.      Touchon, M., Hoede, C., Tenaillon, O., et al. (2009). Organised genome dynamics in the Escherichia coli species results in highly diverse adaptive paths. PLoS genetics, 5(1), e1000344.

3.      Tenaillon, O., Skurnik, D., Picard, B., et al. (2010). The population genetics of commensal Escherichia coli. Nature reviews. Microbiology, 8(3), 207–217.

4.      Croxen, M. A., Law, R. J., Scholz, R., et al. (2013). Recent advances in understanding enteric pathogenic Escherichia coli. Clinical microbiology reviews, 26(4), 822–880.

5.      McWilliams, B. D., Torres, A. G. (2014). EHEC Adhesins. Microbiology spectrum, 2(2), EHEC00032013.

6.      Waksman, G., Hultgren, S. J. (2009). Structural biology of the chaperone-usher pathway of pilus biogenesis. Nature reviews. Microbiology, 7(11), 765–774.

7.      Galán, J. E., Wolf-Watz, H. (2006). Protein delivery into eukaryotic cells by type III secretion machines. Nature, 444(7119), 567–573.

8.      Fleckenstein, J. M., Hardwidge, P. R., Munson, G. P., et al. (2010). Molecular mechanisms of enterotoxigenic Escherichia coli infection. Microbes and infection, 12(2), 89–98.

9.      Flores-Mireles, A. L., Walker, J. N., Caparon, M., et al. (2015). Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nature reviews. Microbiology, 13(5), 269–284.

10.   Spaulding, C. N., Klein, R. D., Ruer, S., et al. (2017). Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Nature, 546(7659), 528–532.

11.   Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet (London, England), 399(10325), 629–655.

12.   Tamma, P. D., Aitken, S. L., Bonomo, R. A., et al. (2022). Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 75(2), 187–212.

13.   Pokharel, P., Dhakal, S., Dozois, C. M. (2023). The Diversity of Escherichia coli Pathotypes and Vaccination Strategies against This Versatile Bacterial Pathogen. Microorganisms, 11(2), 344.

14.   Qiu, L., Chirman, D., Clark, J. R., et al. (2024). Vaccines against extraintestinal pathogenic Escherichia coli (ExPEC): progress and challenges. Gut microbes, 16(1), 2359691.

15.   von Mentzer, A., Svennerholm, A. M. (2024). Colonization factors of human and animal-specific enterotoxigenic Escherichia coli (ETEC). Trends in microbiology, 32(5), 448–464.

16.   Salvador-Erro, J., Pastor, Y., Gamazo, C. (2025). Targeting Enterotoxins: Advancing Vaccine Development for Enterotoxigenic Escherichia coli ETEC. Toxins, 17(2), 71.

17.   Rostamian, M., Shahbazi, S., Lorestani, R. C., et al. (2026). A 25-year landscape of Escherichia coli vaccine development: systematic review of human clinical studies. NPJ vaccines, 11(1), 151.

18.   Dewachter, L., Verstraeten, N., Fauvart, M., et al. (2018). An integrative view of cell cycle control in Escherichia coli. FEMS microbiology reviews, 42(2), 116–136.

19.   Verma, S. C., Qian, Z., Adhya, S. L. (2019). Architecture of the Escherichia coli nucleoid. PLoS genetics, 15(12), e1008456.

20.   Hacker, W. C., Li, S., Elcock, A. H. (2017). Features of genomic organization in a nucleotide-resolution molecular model of the Escherichia coli chromosome. Nucleic acids research, 45(13), 7541–7554.